Palatin Technologies Stock Quote PTN - Stock Price, News, Charts, Message Board, Trades

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

1.15

Bid

Ask

Volume

0.00 Day's Range 0.00

0.68 52 Week Range 5.65

Market Cap

22.48M

Previous Close

1.15

Open

Last Trade

1.13

Last Trade Time

04:15:43

Financial Volume

VWAP

Average Volume (3m)

361,211

Shares Outstanding

19,548,167

Dividend Yield

PE Ratio

-0.76

Earnings Per Share (EPS)

-1.52

Revenue

4.49M

Net Profit

-29.74M

Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its programs are based on molecules that modulate the activity of the me... Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its main product in clinical development is bremelanotide, which treats hypoactive sexual desire disorder, which is a type of female sexual dysfunction. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

palatin.com

Headquarters

Wilmington, Delaware, USA

Founded

Palatin Technologies Inc New is listed in the Pharmaceutical Preparations sector of the American Stock Exchange with ticker PTN. The last closing price for Palatin Technologies was $1.15. Over the last year, Palatin Technologies shares have traded in a share price range of $ 0.68 to $ 5.65.

Palatin Technologies currently has 19,548,167 shares outstanding. The market capitalization of Palatin Technologies is $22.48 million. Palatin Technologies has a price to earnings ratio (PE ratio) of -0.76.

Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy

Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy PR Newswire CRANBURY, N.J., Dec. 19, 2024 Open label study designed to evaluate the...

Form 8-K - Current report

Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds

Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds PR Newswire CRANBURY, N.J., Dec. 16, 2024 CRANBURY, N.J., Dec. 16, 2024 /PRNewswire/ -- Palatin Technologies...

Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis

Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis PR Newswire CRANBURY, N.J., Nov. 25, 2024 Oral PL8177...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results

Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results PR Newswire CRANBURY, N.J., Nov. 14, 2024 Obesity programs:Core focus on obesity includes exploratory co-administration...

Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024

Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024 PR Newswire CRANBURY, N.J., Nov. 8, 2024 CRANBURY, N.J., Nov. 8, 2024...

Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024

Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024 PR Newswire CRANBURY, N.J., Nov. 4, 2024 Oral PL7737 significantly...

Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity

Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity PR Newswire CRANBURY, N.J., Oct...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.1773	18.2276138583	0.9727	1.15	0.91	385596	1.10262977	CS
4	-0.01	-0.862068965517	1.16	1.2	0.7164	648421	0.94264894	CS
12	0.2341	25.5595589038	0.9159	1.4	0.7164	361211	1.00433728	CS
26	-0.79	-40.7216494845	1.94	1.98	0.68	283526	1.09972667	CS
52	-2.81	-70.9595959596	3.96	5.65	0.68	365007	2.02394417	CS
156	0.6104	113.120830245	0.5396	8.6	0.1811	397265	1.2011343	CS
260	0.37	47.4358974359	0.78	8.6	0.1811	1557218	0.75505066	CS

PTN - Frequently Asked Questions (FAQ)

What is the current Palatin Technologies share price?

The current share price of Palatin Technologies is $ 1.15

How many Palatin Technologies shares are in issue?

Palatin Technologies has 19,548,167 shares in issue

What is the market cap of Palatin Technologies?

The market capitalisation of Palatin Technologies is USD 22.48M

What is the 1 year trading range for Palatin Technologies share price?

Palatin Technologies has traded in the range of $ 0.68 to $ 5.65 during the past year

What is the PE ratio of Palatin Technologies?

The price to earnings ratio of Palatin Technologies is -0.76

What is the cash to sales ratio of Palatin Technologies?

The cash to sales ratio of Palatin Technologies is 5.01

What is the reporting currency for Palatin Technologies?

Palatin Technologies reports financial results in USD

What is the latest annual turnover for Palatin Technologies?

The latest annual turnover of Palatin Technologies is USD 4.49M

What is the latest annual profit for Palatin Technologies?

The latest annual profit of Palatin Technologies is USD -29.74M

What is the registered address of Palatin Technologies?

The registered address for Palatin Technologies is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808

What is the Palatin Technologies website address?

The website address for Palatin Technologies is palatin.com

Which industry sector does Palatin Technologies operate in?

Palatin Technologies operates in the PHARMACEUTICAL PREPARATIONS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
ITPIT Tech Packaging Inc	$ 0.452 (55.86%)	702.65k
OPTTOcean Power Technologies Inc	$ 1.14 (29.55%)	2.33M
TPETTrio Petroleum Corp	$ 1.29 (24.04%)	159.42k
CPHIChina Pharma Holdings Inc	$ 0.2398 (21.11%)	8.35k
LODEComstock Inc	$ 1.01 (14.69%)	167.57k
AMBOAmbow Education Holding Ltd	$ 2.99 (-12.32%)	2
ELMDElectromed Inc	$ 27.13 (-10.05%)	303
DITAMCON Distributing Co	$ 122.00 (-7.39%)	101
MSTZT Rex 2X Inverse MSTR Daily Target ETF	$ 23.98 (-7.23%)	207.48k
VNRXVolitionRX Limited	$ 0.5845 (-7.05%)	3k
OPTTOcean Power Technologies Inc	$ 1.14 (29.55%)	2.33M
MSTUT Rex 2X Long MSTR Daily Target ETF	$ 8.92 (6.70%)	738.72k
ITPIT Tech Packaging Inc	$ 0.452 (55.86%)	702.65k
TSLZT Rex 2X Inverse Tesla Daily Target ETF	$ 2.255 (-3.43%)	550.25k
CTMCastellum Inc	$ 2.44 (-5.43%)	389.17k